Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic

Accelerating the Clinical Translation of Cell-Based Therapies Targeting the CNS to Deliver Safe & Efficacious Treatments for Parkinson’s, Alzheimer’s, ALS, MS & Beyond

The Cell Therapy for Neurological Disorders Summit

Advancing Transformative Cell Therapies for CNS Disorders

As CAR-T and other cell therapies revolutionize cancer treatment, their potential for tackling neurological disorders like Alzheimer’s, Parkinson’s, ALS, and MS is sparking new excitement. These innovative therapies could dramatically change the treatment landscape, offering hope to millions of patients worldwide.

The inaugural Cell Therapy for Neurological Disorders Summit is the first industry-focused event dedicated to exploring the latest advancements in cell therapies for neurological disorders. Join leading experts from companies like Kenai Therapeutics, Aspen Neuroscience, NKGen Biotech, UCSD, Coya Therapeutics, and Neurona Therapeutics as they share cutting-edge developments in CAR-T, Treg, stem cell-based therapies, and more. Whether you’re actively engaged in this groundbreaking work or looking to enter the field, this is your chance to connect with a global network of industry and academic thought leaders and drive innovation in neurological care.

Learn from fellow experts looking to bring genuine solutions to patients suffering from neurological disorders.

Sharing our latest research and learning from each other can invigorate our commitment to exploring novel cellular mechanisms and therapeutic strategies
____________________________

Xiaokui Zhang, Chief Scientific Officer, Aspen Neuroscience

“At a time when true disease modifying treatments are lacking in Alzheimer’s disease and Parkinson’s disease, we believe that there is tremendous promise in the use of cell therapies such as natural killer cells, stem cells, and regulatory T-cells”
_______________________________________

Paul Song, Chief Executive Officer, NKGen Biotech